Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
$34.49
$34.46
$10.09
$37.00
$2.26B1.761.71 million shsN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$2.17
+0.7%
$2.06
$1.04
$3.73
$330.30M1.182.18 million shs823,589 shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.74
+0.0%
$0.71
$0.53
$7.11
$119.75M0.32.56 million shs1.03 million shs
Tricida, Inc. stock logo
TCDA
Tricida
$0.13
$0.09
$13.85
$6.01M0.2217.62 million shs31.13 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$12.84
-0.4%
$12.22
$8.33
$17.70
$893.02M1.17584,270 shs285,970 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00%0.00%0.00%0.00%0.00%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
+0.70%+0.23%+8.25%+3.10%-21.84%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
+0.04%-4.91%+21.33%-44.78%-87.89%
Tricida, Inc. stock logo
TCDA
Tricida
0.00%0.00%0.00%0.00%0.00%
Zymeworks Inc. stock logo
ZYME
Zymeworks
-0.43%+3.76%+6.25%+17.21%+52.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.9722 of 5 stars
3.50.00.04.23.31.70.6
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
4.6528 of 5 stars
4.15.00.03.40.60.81.9
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.0155 of 5 stars
3.51.00.00.01.43.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00
N/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.00130.95% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.13
Hold$4.78546.40% Upside
Tricida, Inc. stock logo
TCDA
Tricida
0.00
N/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.90
Moderate Buy$21.0063.62% Upside

Current Analyst Ratings Breakdown

Latest TCDA, ZYME, AIMT, HRTX, and IRWD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$13.00
6/9/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/20/2025
Zymeworks Inc. stock logo
ZYME
Zymeworks
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/16/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/15/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.00
4/15/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $0.70
4/14/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.00
4/14/2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/A$1.66 per shareN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$148.52M2.22N/AN/A($0.22) per share-9.84
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$351.41M0.34$0.05 per share14.95($1.88) per share-0.39
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
$93.38M9.56N/AN/A$6.63 per share1.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$880K-$0.20N/A2.96N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)
Tricida, Inc. stock logo
TCDA
Tricida
-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%7/30/2025 (Estimated)

Latest TCDA, ZYME, AIMT, HRTX, and IRWD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million
5/7/2025Q1 2025
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.73
7.53
7.40
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.40
1.76
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
3.34
3.34
Tricida, Inc. stock logo
TCDA
Tricida
N/A
4.87
4.87
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
74.47%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
Tricida, Inc. stock logo
TCDA
Tricida
N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
13.75%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
5.86%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
12.70%
Tricida, Inc. stock logo
TCDA
Tricida
35.60%
Zymeworks Inc. stock logo
ZYME
Zymeworks
1.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
22865.45 millionN/AOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.62 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
220161.82 million141.27 millionOptionable
Tricida, Inc. stock logo
TCDA
Tricida
5755.67 million35.85 millionNot Optionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
46069.58 million67.56 millionOptionable

Recent News About These Companies

Zymeworks’ zanidatamab approved in China

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aimmune Therapeutics stock logo

Aimmune Therapeutics NASDAQ:AIMT

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$2.16 +0.02 (+0.70%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$2.16 0.00 (0.00%)
As of 07/3/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.74 +0.00 (+0.04%)
As of 07/3/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Tricida stock logo

Tricida NASDAQ:TCDA

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Zymeworks stock logo

Zymeworks NYSE:ZYME

$12.84 -0.06 (-0.43%)
Closing price 07/3/2025 01:45 PM Eastern
Extended Trading
$12.84 0.00 (0.00%)
As of 07/3/2025 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.